NCT02195804已完成1 期
A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formulations Following Oral Administration in Fasting, Healthy Male Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 42
- 主要终点
- Area under the concentration-time curve of ranitidine in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
研究概览
简要总结
The objective of this study is to establish the relative bioavailability (BA) of two different ranitidine hydrochloride 150 mg ODT formulation in comparison to the current, over the counter (OTC) ranitidine hydrochloride (Maximum Strength ZANTAC 150®) formulation following oral single dose administration in fasting healthy male volunteers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects based on: complete medical history, including a physical examination, vital signs (pulse rate (PR), systolic & diastolic blood pressure (BP) and body temperature), 12-lead electrocardiogram (ECG) and clinical laboratory tests
- •Age ≥ 18 and Age ≤ 60 years
- •BMI ≥ 18.5 and BMI ≤ 29.9 kg/m2 (Body Mass Index) and body weight of ≥ 55 kg
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any clinically relevant abnormality found on the screening physical examination (including BP, PR) or ECG or in the opinion of the investigator the patient is not suitable for the study
- •Any evidence of an acute or chronic gastrointestinal conditions or relevant concomitant medical disease
- •History of acute porphyria
- •History of peptic ulcer disease
- •Heartburn requiring treatment (OTC or prescription medicine) within the last 30 days
- •History of surgery of the gastrointestinal tract surgery (except appendectomy and cholecystectomy)
- •History of relevant allergy / hypersensitivity (including allergy to H2 inhibitor) to the drug class, ranitidine hydrochloride or its excipients)
- •Intake of prescription or over-the-counter (OTC) drugs with a long half-life (>24 hours) within at least 2 weeks or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Participation in another trial with an investigational drug within 30 days prior to administration or during the trial
- •Inability to refrain from alcohol use 48 hours prior to drug administration until the end of the study visit for each treatment period
- •History of alcohol (more than 60 g/day) or drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance as determined by the investigator
- •Inability to comply with dietary regimen of trial site
- •Subjects who test positive upon drug screening
- •Subjects who consume caffeine or xanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.) 48 hours prior to study drug administration
- •Subjects who consume citrus fruits and juices, (in particular grapefruits and Seville oranges, sour or bitter oranges), or products containing St. John's wort (Hypericum perforatum) are not allowed 7 days prior to dose administration
- •Excessive physical activity or exercise (such as organized sports) during the trial period
研究组 & 干预措施
Ranitidine HCL ODT Vanilla-Mint
Experimental
干预措施: Ranitidine hydrochloride ODT (Drug)
Ranitidine HCL ODT RM Vanilla-Mint
Experimental
干预措施: Ranitidine hydrochloride ODT RM (Drug)
Ranitidine HCL
Active Comparator
Maximum Strength ZANTAC 150®
干预措施: Ranitidine hydrochloride (Drug)
结局指标
主要结局
Area under the concentration-time curve of ranitidine in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)
时间窗: up to 16 hours after drug administration
Maximum measured concentration of ranitidine in plasma (Cmax)
时间窗: up to 16 hours after drug administration
次要结局
- Terminal half-life of ranitidine in plasma (t1/2)(up to 16 hours after drug administration)
- Global assessment of tolerability by investigator on a 4-point scale(24 hours after drug dosing at the end of each treatment period)
- Area under the concentration-time curve of ranitidine in plasma over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)(up to 16 hours after drug administration)
- Time from dosing to the maximum concentration of ranitidine in plasma (tmax)(up to 16 hours after drug administration)
- Terminal rate constant in plasma (λz)(up to 16 hours after drug administration)
- Mean residence time of the analyte in the body after po administration (MRTpo)(up to 16 hours after drug administration)
- Apparent clearance of the analyte in the plasma after extravascular administration (CL/F)(up to 16 hours after drug administration)
- Apparent volume of distribution during the terminal phase λz following an extravascular dose (Vz/F)(up to 16 hours after drug administration)
- Number of patients with adverse events(up to 38 days)
研究者
相似试验
已完成
1 期
Topiramate Bioequivalence Study Brazil - FastEpilepsy, Tonic-ClonicNCT01439438GlaxoSmithKline26
已完成
1 期
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New FormulationPharmacokinetics of ASP015KBioavailability of ASP015KHealthy SubjectsNCT01484964Astellas Pharma Inc24
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fasted ConditionsHealthyNCT01418586Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Alfuzosin ER Tablets Under Fed ConditionsHealthyNCT01418599Torrent Pharmaceuticals Limited
撤回
1 期
Bioequivalence Study of Gliclazide 120 mg Modified Release TabletsComparative BioavailabilityNCT02980757Disphar International B.V.